Pharmacological therapy for female sexual dysfunction: has progress been made?
The investigation of female sexual dysfunction (FSD) is an evolving area in which definitions and models for female sexual functioning are being continually reviewed and revised. The lack of consensus amongst experts in the field and regulating authorities regarding appropriate inclusion and exclusion criteria for FSD trials, and main outcome measures appropriate for the evaluation of drug interventions has somewhat hampered progression in this area. Nonetheless, there is evidence from randomized controlled trials that androgen therapy improves the quality of the sexual experience for postmenopausal women with low libido, and preliminary data that this may also apply to premenopausal women.
Davis
Susan R
SR
Women's Health Program, Department of Medicine, Monash University, Prahran, Victoria, Australia. Susan.Davis@med.monash.edu.au
Nijland
Esme A
EA
D045930:Anabolic Agents / Q000627:therapeutic use*; D000728:Androgens / Q000627:therapeutic use*; D004967:Estrogens / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D009652:Norpregnenes / Q000627:therapeutic use; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D012735:Sexual Dysfunction, Physiological / Q000188:drug therapy*; D020018:Sexual Dysfunctions, Psychological / Q000188:drug therapy*; D013739:Testosterone / Q000627:therapeutic use
D045930:Anabolic Agents; D000728:Androgens; D004967:Estrogens; D009652:Norpregnenes; D010726:Phosphodiesterase Inhibitors; D013739:Testosterone; C027385:tibolone